Overweight

Novo Nordisk and the FDA announced approval of a new indication for semaglutide 2.4 mg for reduction of risk for major adverse cardiovascular events in adults with overweight or obesity and established CVD.

Deteriorating quality of life for women with breast cancer was associated with many common modifiable psychosocial and lifestyle-related factors, according to an analysis published in JAMA Network Open.

Men who had a lower birth weight followed by overweight during young adulthood have a greatly increased risk for developing type 2 diabetes vs. those with normal weight at those times, according to study results published in Diabetologia.

An increase in symptoms of depression was linked to a small increase in weight among adults with overweight or obesity, according to a recent study in PLOS One.

As the first point of contact for many patients, it is important for primary care physicians to have strategies that will help treat and manage overweight and obesity, according to experts.

PHILADELPHIA — In the SELECT trial, treatment with weekly injectable semaglutide 2.4 mg was superior to placebo for reducing cardiovascular risk in adults with preexisting heart disease and overweight or obesity but without diabetes.

The FDA approved the injectable GIP/GLP-1 dual incretin-based agonist tirzepatide for chronic weight management among adults with obesity, according to a press release.

CV deaths related to obesity increased by 200% across all race groups from 1999 to 2020, a statistic researchers said reflects the health consequences of the rising burden of obesity in the United States.

DANA POINT, Calif. — In this Healio video exclusive, Fatima Cody Stanford, MD, MPA, MPH, MBA, discusses considerations clinicians must make regarding women with obesity.

Adults with overweight or obesity in the U.S. have a one in 10 annual probability of achieving a 5% or greater weight loss, and the likelihood for weight loss increases with a higher initial BMI, according to study data.